These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 21952622)

  • 1. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.
    Kote-Jarai Z; Leongamornlert D; Saunders E; Tymrakiewicz M; Castro E; Mahmud N; Guy M; Edwards S; O'Brien L; Sawyer E; Hall A; Wilkinson R; Dadaev T; Goh C; Easton D; ; Goldgar D; Eeles R
    Br J Cancer; 2011 Oct; 105(8):1230-4. PubMed ID: 21952622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subgroups of familial and aggressive prostate cancer with considerable frequencies of BRCA2 mutations.
    Maier C; Herkommer K; Luedeke M; Rinckleb A; Schrader M; Vogel W
    Prostate; 2014 Oct; 74(14):1444-51. PubMed ID: 25111659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer.
    Maia S; Cardoso M; Paulo P; Pinheiro M; Pinto P; Santos C; Pinto C; Peixoto A; Henrique R; Teixeira MR
    Fam Cancer; 2016 Jan; 15(1):111-21. PubMed ID: 26289772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.
    Edwards SM; Evans DG; Hope Q; Norman AR; Barbachano Y; Bullock S; Kote-Jarai Z; Meitz J; Falconer A; Osin P; Fisher C; Guy M; Jhavar SG; Hall AL; O'Brien LT; Gehr-Swain BN; Wilkinson RA; Forrest MS; Dearnaley DP; Ardern-Jones AT; Page EC; Easton DF; Eeles RA;
    Br J Cancer; 2010 Sep; 103(6):918-24. PubMed ID: 20736950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene.
    Edwards SM; Kote-Jarai Z; Meitz J; Hamoudi R; Hope Q; Osin P; Jackson R; Southgate C; Singh R; Falconer A; Dearnaley DP; Ardern-Jones A; Murkin A; Dowe A; Kelly J; Williams S; Oram R; Stevens M; Teare DM; Ponder BA; Gayther SA; Easton DF; Eeles RA; ;
    Am J Hum Genet; 2003 Jan; 72(1):1-12. PubMed ID: 12474142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer.
    Leon P; Cancel-Tassin G; Bourdon V; Buecher B; Oudard S; Brureau L; Jouffe L; Blanchet P; Stoppa-Lyonnet D; Coulet F; Sobol H; Cussenot O
    Prostate; 2021 May; 81(6):318-325. PubMed ID: 33599307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline BRCA1 mutations increase prostate cancer risk.
    Leongamornlert D; Mahmud N; Tymrakiewicz M; Saunders E; Dadaev T; Castro E; Goh C; Govindasami K; Guy M; O'Brien L; Sawyer E; Hall A; Wilkinson R; Easton D; ; Goldgar D; Eeles R; Kote-Jarai Z
    Br J Cancer; 2012 May; 106(10):1697-701. PubMed ID: 22516946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer.
    Agalliu I; Karlins E; Kwon EM; Iwasaki LM; Diamond A; Ostrander EA; Stanford JL
    Br J Cancer; 2007 Sep; 97(6):826-31. PubMed ID: 17700570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer.
    Lee DJ; Hausler R; Le AN; Kelly G; Powers J; Ding J; Feld E; Desai H; Morrison C; Doucette A; Gabriel P; Genetics Center R; Judy RL; Weaver J; Kember R; Damrauer SM; Rader DJ; Domchek SM; Narayan V; Schwartz LE; Maxwell KN
    Eur Urol; 2022 Jun; 81(6):559-567. PubMed ID: 34711450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Genes with Rare Loss of Function Variants Associated with Aggressive Prostate Cancer and Survival.
    Saunders EJ; Dadaev T; Brook MN; Wakerell S; Govindasami K; Rageevakumar R; Hussain N; Osborne A; Keating D; Lophatananon A; Muir KR; ; Darst BF; Conti DV; Haiman CA; Antoniou AC; Eeles RA; Kote-Jarai Z
    Eur Urol Oncol; 2024 Apr; 7(2):248-257. PubMed ID: 38458890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes.
    Kote-Jarai Z; Mikropoulos C; Leongamornlert DA; Dadaev T; Tymrakiewicz M; Saunders EJ; Jones M; Jugurnauth-Little S; Govindasami K; Guy M; Hamdy FC; Donovan JL; Neal DE; Lane JA; Dearnaley D; Wilkinson RA; Sawyer EJ; Morgan A; Antoniou AC; Eeles RA;
    Ann Oncol; 2015 Apr; 26(4):756-761. PubMed ID: 25595936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in hereditary prostate cancer.
    Tischkowitz M; Sabbaghian N; Ray AM; Lange EM; Foulkes WD; Cooney KA
    Prostate; 2008 May; 68(6):675-8. PubMed ID: 18288683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rare germline genetic variants and risk of aggressive prostate cancer.
    Nguyen-Dumont T; MacInnis RJ; Steen JA; Theys D; Tsimiklis H; Hammet F; Mahmoodi M; Pope BJ; Park DJ; Mahmood K; Severi G; Bolton D; Milne RL; Giles GG; Southey MC
    Int J Cancer; 2020 Oct; 147(8):2142-2149. PubMed ID: 32338768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype.
    Mitra A; Fisher C; Foster CS; Jameson C; Barbachanno Y; Bartlett J; Bancroft E; Doherty R; Kote-Jarai Z; Peock S; Easton D; ; Eeles R
    Br J Cancer; 2008 Jan; 98(2):502-7. PubMed ID: 18182994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline mutations in the BRCA2 gene and susceptibility to hereditary prostate cancer.
    Agalliu I; Kwon EM; Zadory D; McIntosh L; Thompson J; Stanford JL; Ostrander EA
    Clin Cancer Res; 2007 Feb; 13(3):839-43. PubMed ID: 17289875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications.
    Brandão A; Paulo P; Teixeira MR
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India.
    Saxena S; Chakraborty A; Kaushal M; Kotwal S; Bhatanager D; Mohil RS; Chintamani C; Aggarwal AK; Sharma VK; Sharma PC; Lenoir G; Goldgar DE; Szabo CI
    BMC Med Genet; 2006 Oct; 7():75. PubMed ID: 17018160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group.
    Anglian Breast Cancer Study Group
    Br J Cancer; 2000 Nov; 83(10):1301-8. PubMed ID: 11044354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.
    Saunders EJ; Dadaev T; Leongamornlert DA; Al Olama AA; Benlloch S; Giles GG; Wiklund F; Gronberg H; Haiman CA; Schleutker J; Nordestgaard BG; Travis RC; Neal D; Pasayan N; Khaw KT; Stanford JL; Blot WJ; Thibodeau SN; Maier C; Kibel AS; Cybulski C; Cannon-Albright L; Brenner H; Park JY; Kaneva R; Batra J; Teixeira MR; Pandha H; Govindasami K; Muir K; ; ; ; Easton DF; Eeles RA; Kote-Jarai Z
    Br J Cancer; 2016 Apr; 114(8):945-52. PubMed ID: 26964030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.